Grants and Contracts Details
| Status | Finished |
|---|---|
| Effective start/end date | 8/11/10 → 12/31/11 |
Funding
- Neuraltus Pharmaceuticals Incorporated: $13,725.00
Single-Ascending-Dose Safety and Tolerability Study of NP001 in Patients with Amvotrophic Lateral Sclerosis (ALS)
- Kasarskis, Edward (PI)